|
Prerequisites of Pharmacological Consideration with the case of Liver Ischemia reperfusion injury
|
|
| Author:
|
ALLA , MIKHAIL V. POKROVSKIY, KONSTANTIN S. TRUNOV, ANTON P. DANILENKO, YULIA V. STEPENKO, GALINA A. BATISCHEVA, PAVEL A. GALENKO-YAROSHEVSKIY
|
| Abstract:
|
Introduction: Experimental and clinical data accumulated over the past decade indicate a number of pleiotropic effects that are inherent in incretinomimetics. These effects are due to the wide distribution of GLP-1 receptors (GLP-1R) in many organs and tissues.
Objective: Study of hepatoprotective activity of exenatide and vildagliptin on the liver ischemia/reperfusion model, taking into account biochemical and morphological parameters.
Methods: Ischemia-reperfusion injury of the liver was reproduced by 15-minute clamping of the rat liver-duodenal ligament analogue with subsequent restoration of blood flow and removal of the animal from the experiment on the 3rd day. Exenatide at a dose of 10 µg/kg was administered subcutaneously, vildagliptin orally at a dose of 0.2 mg/kg 2 hours before the experiment.
Results: Exenatide (10 µg/kg) and vildagliptin (0.2 mg/kg) reduced hepatocellular ischemia/reperfusion injury, which resulted in preventing the increased activity of AST and ALT transaminases, reducing necrosis areas by 1.9 times (compared with the ischemia/reperfusion group), reducing the infiltration of stromal and parenchymal elements of the liver, reducing edema.
Conclusion: The hepatoprotective effects of exenatide and vildagliptin identify them as potentially effective drugs for correcting ischemic/reperfusion injury of the liver.
|
| Keyword:
|
Ischemia-reperfusion, liver, incretinomimetics, exenatide, vildagliptin, hepatoprotection
|
| EOI:
|
-
|
| DOI:
|
https://doi.org/10.31838/ijpr/2019.11.04.0307
|
| Download:
|
Request For Article
|
|
|